Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
10.15
-0.02 (-0.20%)
Mar 24, 2026, 1:33 PM EDT - Market open
Design Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
54
Market Cap
625.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 418.63M |
| Gyre Therapeutics | 116.59M |
| Lexicon Pharmaceuticals | 49.80M |
| Prime Medicine | 4.63M |
| Ocugen | 4.41M |
DSGN News
- 14 days ago - Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 4 weeks ago - Design Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 6 months ago - Design Therapeutics Appoints Justin Gover to Board of Directors - GlobeNewsWire
- 7 months ago - Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 7 months ago - Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference - GlobeNewsWire
- 8 months ago - Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 10 months ago - Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 - GlobeNewsWire